Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Indivior selects CRO to conduct phase I study of INDV-2000

Dec. 10, 2019

Adamis Pharmaceuticals receives a complete response letter regarding Zimhi

Nov. 26, 2019

Binging brains give themselves away

Nov. 26, 2019

Diabetes drug eases nicotine withdrawal

Nov. 14, 2019

New phase II trial studies suvorexant for comorbid sleep disorder and alcohol dependence

Oct. 24, 2019

Dosing begins in NIH-funded phase II proof-of-concept study of ANS-6637

Oct. 18, 2019

AstraZeneca initiates first-in-human study of AZD-4041 in healthy volunteers

Oct. 15, 2019

Humanetics' development of radioprotectant BIO-301 supported by DoD cooperative research agreement

Oct. 2, 2019

NIDA grant supports Kinoxis' development of KNX-100 for opioid withdrawal

Oct. 1, 2019

Emergent BioSolutions, Indivior win NIH grants to study drugs for opioid use disorder

Sep. 30, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.